A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. (Q48136103)
Jump to navigation
Jump to search
scientific article published in January 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. |
scientific article published in January 2014 |
Statements
1 reference
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. (English)
1 reference
1 reference
Richard A Grove
1 reference
Conn M Harrington
1 reference
Andreas Mahler
1 reference
Isabel Beresford
1 reference
Martin T Lowy
1 reference
Andrew P Nicholls
1 reference
Rebecca L Boardley
1 reference
Alienor C Berges
1 reference
Pradeep J Nathan
1 reference
Joseph P Horrigan
1 reference
1 January 2014
1 reference
1 reference
11
1 reference
47-58
1 reference
1
1 reference
Identifiers
1 reference